185750 — Chong Kun Dang Pharmaceutical Income Statement
0.000.00%
Last trade - 00:00- KR₩1tn
- KR₩1tn
- KR₩2tn
- 72
- 50
- 43
- 58
Annual income statement for Chong Kun Dang Pharmaceutical, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,303,006 | 1,343,559 | 1,488,345 | 1,669,404 | 1,586,431 |
| Cost of Revenue | |||||
| Gross Profit | 489,140 | 495,818 | 542,639 | 662,202 | 532,611 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 1,179,070 | 1,248,801 | 1,382,351 | 1,422,202 | 1,487,893 |
| Operating Profit | 123,936 | 94,759 | 105,994 | 247,203 | 98,538 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 121,839 | 80,594 | 97,165 | 241,598 | 102,009 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 90,405 | 42,356 | 79,978 | 213,602 | 111,442 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 91,633 | 42,720 | 80,953 | 212,521 | 109,073 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 91,633 | 42,720 | 80,953 | 212,521 | 109,073 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 6,634 | 3,110 | 6,229 | 15,861 | 7,878 |
| Dividends per Share |